Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Castrate Resistance Prostate Cancer · OligoProgressive Metastatic Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Princess Margaret Cancer Center, Toronto, Ontario, Canada
Contact: Study coordinator (Rachel Glicksman, MD) · rachel.glicksman@rmp.uhn.ca · 416-946-4483

Study leads

Rachel Glicksman, MD
Principal Investigator
Princess Margaret Cancer Centre - University Health Network

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Breast Cancer · Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Charlottesville, United States

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

mCRPC (Metastatic Castration-resistant Prostate Cancer) · Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Fountain Valley, United States · Los Alamitos, United States

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Prostate Cancer · Metastatic Castration-resistant Prostate Cancer · mCRPC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Miami, United States · Miami, United States

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

Metastatic Castration-resistant Prostate Cancer · Metastatic Prostate Cancer · Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

London, United Kingdom